Oler, Jonathan A.
Tromp, Do P. M.
Fox, Andrew S.
Kovner, Rothem
Davidson, Richard J.
Alexander, Andrew L.
McFarlin, Daniel R.
Birn, Rasmus M.
E. Berg, Benjamin
deCampo, Danielle M.
Kalin, Ned H.
Fudge, Julie L.
Funding for this research was provided by:
National Institute of Mental Health (R01-MH046729, R01-MH063291, F30-MH096502, R01-MH081884, P50-MH084051, T32-MH018931)
NIH Office of the Director (P51OD011106)
National Institute of Neurological Disorders and Stroke (T32- NS007 489-09)
National Institutes of Health (RR15459-01, RR020141-01)
Article History
Received: 6 August 2015
Accepted: 30 January 2016
First Online: 23 February 2016
Compliance with ethical standards
:
: Dr. Kalin has received honoraria from CME Outfitters, Elsevier, and the Pritzker Neuropsychiatric Disorders Research Consortium. He is on the Advisory Boards for Corcept Therapeutics and Skyland Trail-George West Mental Health Foundation. Dr. Kalin is a Stockholder in Corcept Therapeutics, and owns several patents including: promoter sequences for corticotropin-releasing factor alpha (U.S. Patent #7071323, issued on 07-04-06); a method of identifying agents that alter the activity of the promoter sequences (U.S. Patent #7531356 issued on 05-12-09); promoter sequences for urocortin II and the use thereof (U.S. Patent #7087385 issued on 08-08-06); and promoter sequences for corticotropin-releasing factor binding protein and use thereof (U.S. Patent #7122650, issued on 10-17-06). All other authors declare no conflicts of interest.